MX2019000508A - Radioligandos para formar la imagen de la enzima indolamina 2,3-dioxigenasa (ido1). - Google Patents
Radioligandos para formar la imagen de la enzima indolamina 2,3-dioxigenasa (ido1).Info
- Publication number
- MX2019000508A MX2019000508A MX2019000508A MX2019000508A MX2019000508A MX 2019000508 A MX2019000508 A MX 2019000508A MX 2019000508 A MX2019000508 A MX 2019000508A MX 2019000508 A MX2019000508 A MX 2019000508A MX 2019000508 A MX2019000508 A MX 2019000508A
- Authority
- MX
- Mexico
- Prior art keywords
- imaging
- radioligands
- ido1 enzyme
- ido1
- enzyme
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Quinoline Compounds (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662364020P | 2016-07-19 | 2016-07-19 | |
| PCT/US2017/042510 WO2018017529A1 (en) | 2016-07-19 | 2017-07-18 | Radioligands for imaging the ido1 enzyme |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000508A true MX2019000508A (es) | 2019-03-28 |
Family
ID=59416832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000508A MX2019000508A (es) | 2016-07-19 | 2017-07-18 | Radioligandos para formar la imagen de la enzima indolamina 2,3-dioxigenasa (ido1). |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20190282714A1 (enExample) |
| EP (1) | EP3487516A1 (enExample) |
| JP (1) | JP6987840B2 (enExample) |
| KR (1) | KR102513886B1 (enExample) |
| CN (1) | CN109475594A (enExample) |
| AU (1) | AU2017298262B2 (enExample) |
| BR (1) | BR112019000499A2 (enExample) |
| CA (1) | CA3031079A1 (enExample) |
| EA (1) | EA039877B1 (enExample) |
| IL (1) | IL264187B (enExample) |
| MX (1) | MX2019000508A (enExample) |
| SG (1) | SG11201900336YA (enExample) |
| WO (1) | WO2018017529A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019528300A (ja) * | 2016-08-26 | 2019-10-10 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | インドールアミン2,3−ジオキシゲナーゼの阻害剤およびその使用方法 |
| WO2019006292A1 (en) * | 2017-06-30 | 2019-01-03 | Bristol-Myers Squibb Company | SUBSTITUTED QUINOLINYCYCLOHEXYLPROPANAMIDE COMPOUNDS AND IMPROVED PROCESSES FOR THE PREPARATION THEREOF |
| KR20200088410A (ko) * | 2017-11-21 | 2020-07-22 | 광동 오포 모바일 텔레커뮤니케이션즈 코포레이션 리미티드 | 정보 전송 방법, 네트워크 디바이스 및 단말기 디바이스 |
| EP3720843A1 (en) * | 2017-12-05 | 2020-10-14 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
| CN110357813A (zh) * | 2018-04-09 | 2019-10-22 | 信达生物制药(苏州)有限公司 | 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途 |
| AR120935A1 (es) * | 2020-01-02 | 2022-03-30 | Hutchison Medipharma Ltd | Derivados de amida y usos de los mismos |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101182359A (zh) * | 2007-11-09 | 2008-05-21 | 中山大学 | 人吲哚胺2,3-双加氧酶多克隆抗体及其制备方法和应用 |
| WO2011109262A2 (en) * | 2010-03-01 | 2011-09-09 | Tau Therapeutics Llc | Cancer diagnosis and imaging |
| WO2016040458A2 (en) * | 2014-09-09 | 2016-03-17 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Pet probes of radiofluorinated carboximidamides for ido-targeted imaging |
| UY36390A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
-
2017
- 2017-07-18 EA EA201990198A patent/EA039877B1/ru unknown
- 2017-07-18 US US16/318,209 patent/US20190282714A1/en not_active Abandoned
- 2017-07-18 CN CN201780044908.4A patent/CN109475594A/zh active Pending
- 2017-07-18 KR KR1020197004720A patent/KR102513886B1/ko active Active
- 2017-07-18 SG SG11201900336YA patent/SG11201900336YA/en unknown
- 2017-07-18 BR BR112019000499-8A patent/BR112019000499A2/pt unknown
- 2017-07-18 AU AU2017298262A patent/AU2017298262B2/en active Active
- 2017-07-18 WO PCT/US2017/042510 patent/WO2018017529A1/en not_active Ceased
- 2017-07-18 MX MX2019000508A patent/MX2019000508A/es unknown
- 2017-07-18 CA CA3031079A patent/CA3031079A1/en active Pending
- 2017-07-18 EP EP17745597.9A patent/EP3487516A1/en active Pending
- 2017-07-18 JP JP2019503232A patent/JP6987840B2/ja active Active
-
2019
- 2019-01-10 IL IL264187A patent/IL264187B/en active IP Right Grant
-
2022
- 2022-04-18 US US17/722,628 patent/US20220305144A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019000499A2 (pt) | 2019-04-24 |
| US20190282714A1 (en) | 2019-09-19 |
| US20220305144A1 (en) | 2022-09-29 |
| JP2019527225A (ja) | 2019-09-26 |
| AU2017298262B2 (en) | 2024-07-18 |
| IL264187A (en) | 2019-02-28 |
| CA3031079A1 (en) | 2018-01-25 |
| KR102513886B1 (ko) | 2023-03-27 |
| WO2018017529A1 (en) | 2018-01-25 |
| KR20190030727A (ko) | 2019-03-22 |
| AU2017298262A1 (en) | 2019-03-07 |
| EP3487516A1 (en) | 2019-05-29 |
| CN109475594A (zh) | 2019-03-15 |
| EA201990198A1 (ru) | 2019-06-28 |
| JP6987840B2 (ja) | 2022-01-05 |
| SG11201900336YA (en) | 2019-02-27 |
| IL264187B (en) | 2021-06-30 |
| EA039877B1 (ru) | 2022-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019000508A (es) | Radioligandos para formar la imagen de la enzima indolamina 2,3-dioxigenasa (ido1). | |
| HUS2200011I1 (hu) | Készítmények és eljárások HAO1 (hidroxisav-oxidáz-1 (glikolát-oxidáz)) gén expressziójának gátlására | |
| ZA201906822B (en) | Indole ahr inhibitors and uses thereof | |
| GEP20217234B (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
| ZA201903984B (en) | Methods of using thermostable serine proteases | |
| GEP20207151B (en) | Agents, Uses and Methods for the Treatment of Synucleinopathy | |
| PH12018500397A1 (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG10201902813XA (en) | Methods and materials for biosynthesis of mogroside compounds | |
| PH12015502048A1 (en) | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same | |
| SG10202102897PA (en) | Compositions and methods for the depletion of cd137+ cells | |
| EA039598B9 (ru) | Соединение, нацеленное на ил-23а и фно-альфа, и его применение | |
| PH12017500841B1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| AU2017317563A8 (en) | Detergent compositions comprising xanthan lyase variants I | |
| NZ725917A (en) | Novel polymerase-i inhibitors, uses and methods for making them | |
| MX375892B (es) | Composición que comprende sal de glutamato de acilo como tensoactivo principal o tensoactivo principal aniónico | |
| PH12017501043A1 (en) | 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| MX2023012628A (es) | Metodos y composiciones para deteccion y diagnostico de enfermedades renales y enfermedades periodontales. | |
| MX2018016037A (es) | Variantes de lipasa y composiciones que comprenden tensioactivo y variante de lipasa. | |
| MX2018007083A (es) | Sintesis diaestereoselectiva de derivados de fosfato y del profarmaco de gemcitabina nuc-1031. | |
| WO2016079110A3 (en) | Use of enzyme for cleaning | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| SG11202012762WA (en) | Methods and compositions for cluster generation by bridge amplification | |
| IN2014DN00254A (enExample) | ||
| MX388832B (es) | Deteccion especifica de isoformas de clusterina. | |
| MX2016009056A (es) | Composiciones y metodos para tratamiento de crecimiento celular anormal. |